Viral infections: Current diagnosis and treatment

Hematology Journal

Volumn 5, Issue SUPPL. 3, 2004, Pages

  Ljungman, Per ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; AMANTADINE; ANTIVIRUS AGENT; CIDOFOVIR; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; INFLUENZA VACCINE; OSELTAMIVIR; RIBAVIRIN; RIMANTADINE; RITUXIMAB; VALACICLOVIR; ZANAMIVIR;

ADENOVIRUS; ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHICKENPOX; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; GASTROINTESTINAL INFECTION; HERPES SIMPLEX; HUMAN; HUMAN HERPESVIRUS 6; INFECTION RISK; INFLUENZA; LYMPHOPROLIFERATIVE DISEASE; POLYMERASE CHAIN REACTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK FACTOR; SEROLOGY; VIRUS ENCEPHALITIS; VIRUS HEPATITIS; VIRUS INFECTION; VIRUS LOAD; VIRUS PNEUMONIA; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; PREMEDICATION; PROGNOSIS; RISK FACTORS; VIRUS DISEASES;

EID: 4043133065     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200425     Document Type: Article

References (20)

1. Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100: 768-773.
2. Nguyen Q, Estey E, Raad I, Rolston K, Kantarjian H, Jacobson K et al. Cytomegalovirus pneumonia in adults with leukemia: an emerging problem. Clin Infect Dis 2001; 32: 539-545.
3. Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003; 101: 407-414.
4. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
5. Machado CM, Dulley FL, Boas LS, Castelli JB, Macedo MC, Silva RL et al. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy. Bone Marrow Transplant 2000; 26: 413-417.
6. Ljungman P, Deliliers GL, Platzbecker U, Matthes-Martin S, Bacigalupo A, Einsele H et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2001; 97: 388-392
7. Bowden R, Cays M, Schoch G, Sayers M, Slichter S, Welk K et al. Comparison of filtered blood (FB) to seronegative blood products (SB) for prevention of cytomegalovirus (CMV) infection after marrow transplant. Blood 1995; 86: 3598-3603.
8. Winston DJ, Yeager AM, Chandrasekar PH, Snydman DR, Petersen FB, Territo MC. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis 2003; 36: 749-758.
9. Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002; 99: 1159-1164.
10. Nichols WG, Corey L, Gooley T, Drew WL, Miner R, Huang M et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 2001; 97: 867-874.
11. Gartner BC, Schafer H, Marggraff K, Eisele G, Schafer M, Roemer K et al. Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease. J Clin Microbiol 2002; 40: 351-358.
12. Wang FZ, Linde A, Hagglund H, Testa M, Locasciulli A, Ljungman P. Human herpesvirus 6 DNA in cerebrospinal fluid specimens from allogeneic bone marrow transplant patients: does it have clinical significance? Clin Infect Dis 1999; 28: 562-568.
13. Zerr DM, Gupta D, Huang ML, Carter R, Corey L. Effect of antivirals on human herpesvirus 6 replication in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 309-317.
14. Whimbey E, Couch RB, Englund JA, Andreeff M, Goodrich JM, Raad II et al. Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis 1995; 21: 376-379.
15. Martino R, Ramila E, Rabella N, Munoz JM, Peyret M, Portos JM et al. Respiratory virus infections in adults with hematologic malignancies: a prospective study. Clin Infect Dis 2003; 36: 1-8.
16. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001; 98: 573-578.
17. Sparrelid E, Ljungman P, Ekelof-Andstrom E, Aschan J, Ringden O, Winiarski J et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant 1997; 19: 905-908.
18. Whimbey E, Elting LS, Couch RB, Lo W, Williams L, Champlin RE et al. Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant 1994; 13: 437-440.
19. Ljungman P, Ward KN, Crooks BN, Parker A, Martino R, Shaw PJ et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transp1ant 2001; 28: 479-484.
20. Ljungman P, Ribaud P, Eyrich M, Matthes-Martin S, Einsele H, Bleakley M et al. Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2003; 31: 481-486.